checkAd

     105  0 Kommentare SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results - Seite 4

    These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, as amended, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

    Contacts

    Media Relations: khollon@sab.bio

    Investor Relations: matt@milestone-advisorsllc.com

    CONTACT: Media Relations: khollon@sab.bio
    
    Investor Relations: matt@milestone-advisorsllc.com

    Seite 4 von 4




    globenewswire
    0 Follower
    Autor folgen
    Verfasst von globenewswire
    SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results - Seite 4 Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) - SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed financing for up to $110 million …